Accelerated approval was based on the Phase 2 RAMP 201 study that demonstrated a 44% overall response rate in patients with KRAS-mutated recurrent low-grade serous ovarian cancer, the company said.

The blue-chip Dow Jones Industrial Average was on pace to exit correction territory on Thursday, after briefly flirting with bear-market territory during the lows of April sparked by President Trump's ...

U.K. trade front as a hopeful sign that more agreements can be reached, as President Trump starts making some headway on the trade fight he started months ago, said Peter Cardillo, chief market ...

Investors didn't rush out to buy U.K. stocks on Thursday, with the FTSE 100 index shedding 0.3% and booking a second straight day of losses, according to Dow Jones Market Data. While called a ...

Buoyed by strong returns for shares of Boeing and Walt Disney, the Dow Jones Industrial Average is rallying Thursday afternoon.

Gold prices settled lower on Thursday as growing trade-deal optimism boosted risk-on sentiment and fueled a rise in the U.S. stock market, noted Fawad Razaqzada, market analyst at City Index and FOREX ...

Energy and consumer-discretionary stocks, which could be extra sensitive to economic weakness, were surging on Thursday on trade optimism. The S&P 500's energy sector was up 2%, while its ...

The Trump administration's approach to trade discussions has taken a clear shift toward de-escalation rather than confrontation, according to TD Securities. This shift could lead to a framework for ...

A Fix My Portfolio reader shares how they avoided a “tax bomb” in retirement through Roth conversions and careful financial ...

Verastem Oncology said the Food and Drug Administration approved the combination of avutometinib capsules and defactinib tablets for certain patients with KRAS-mutated recurrent low-grade serous ...

WeBuy Global shares surged 224% to $9.92 as the stock returned to Nasdaq and the e-commerce company reported strong travel growth. The stock is down about 52% this year.

Dave Inc. shares were 38% higher, at $148.33, after the company reported first-quarter earnings that beat estimates, and after it raised its 2025 revenue guidance.